Table 2.
Clinicopathological and Genomic Findings Based on the Clinical Responses to Mogamulizumab.
| Reponder group (CR+PR) |
Non-Responder group (SD+PD) |
p value | ||||
|---|---|---|---|---|---|---|
| Clinical characteristics (n=22) | (n=15) | (n=7) | ||||
| Age Median (range) | 67 (46-79) | 63 (53-80) | 0.48 | |||
| Sex | ||||||
| Male (%) | 5 (33) | 3 (43) | ||||
| Subtype | 0.334 | |||||
| Lymphoma | 3 | 3 | ||||
| Acute | 12 | 4 | ||||
| sATL-PI | 0.648 | |||||
| Low | 0 | 0 | ||||
| Intermediate | 8 | 5 | ||||
| High | 7 | 2 | ||||
| Clinical status prior mogamulizumab | 0.523 | |||||
| PR | 3 | 0 | ||||
| PD | 12 | 7 | ||||
| Pathological characteristics (n=14) | (n=8) | (n=6) | ||||
| CD3, positive (%) | 7 (88) | 6 (100) | 1 | |||
| CD4, positive (%) | 6 (75) | 5 (83) | 1 | |||
| CD8, positive (%) | 2 (25) | 0 (0) | 0.473 | |||
| FOXP3, positive (%) | 3 (38) | 2 (33) | 1 | |||
| CCR4, positive (%) | 7 (86) | 5 (83) | 1 | |||
| CCR4 global score, average (range) | 8.4 (1-12) | 4.2 (0-12) | 0.099 | |||
| HLA class1, positive (%) | 6 (75) | 4 (67) | 1 | |||
| HLA class2, positive (%) | 3 (38) | 3 (50) | 1 | |||
| PDL1, positive in neoplastic cells (%) | 1 (13) | 1 (17) | 1 | |||
| PDL1, positive in microenvironment (%) | 4 (50) | 3 (50) | 1 | |||
| PD-1 positive TIL, counts/HPF average (range) | 1.9 (0-10) | 6.4 (0-20) | 0.156 | |||
| CCR 4 mutation | 2 (25) | 4 (67) | 0.277 |